How to Cope With Post-Pandemic Anxiety

Young woman sits in window sill while looking at phone

With vaccination efforts ramping up across the United States, people are looking forward to a sense of normalcy. However, for many, the thought of things returning to normal brings a paralyzing sense of anxiety. Shannon O’Neill, PhD, licensed psychologist and Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, discusses the post-pandemic anxiety you may be experiencing and how to overcome those complicated feelings.

Why are people feeling anxious as we see signs of the pandemic easing?

It makes a lot of sense that people are feeling anxious and unsettled right now. Just when we were finally adjusting to a new normal with some predictability and flow, the world is preparing to change all over again. Future uncertainty and a sense of not knowing what to expect can fuel anticipatory anxiety. There is even a diagnosis for this feeling: adjustment disorder.

What does that mean?

Adjustment disorder is described as an emotional or behavioral reaction to stress or change in a person’s life. As vaccinations tick up and warmer weather approaches, there will likely be a significant readjustment of phasing normalcy back into our lives, similar to the adjustments made to social distancing or quarantining at home. This can, naturally, cause feelings of anxiety, as well as depression.

In most circumstances, beginning to reintegrate a ‘normal’ routine can enhance ones confidence. So, having the extra protection of the vaccine amongst ourselves and within our community may offer added physical and emotional security for those who are feeling anxious about things going back to normal.

How can I overcome the new feelings of anxiety I’ve developed during quarantine?

A classic treatment approach for an anxiety diagnosis is exposure. Rather than avoiding what is feared, it is important to lean into those activities.

Technology has been a wonderful and very helpful incentive for us to stay home when it was important to do so. Whether enabling us to receive a grocery or pharmacy delivery or attend a virtual happy hour, technology has allowed us to obtain resources and socialize from a distance. However, for some, this adaptation can turn into over accommodation and avoidance.

Thankfully, through repeated exposures to feared stimuli, while also following CDC guidelines, you should eventually become more comfortable. However, this may mean that you will need to ease in with smaller social commitments that have time limits before expanding out to larger outings. For instance, if attending an extended outing with your larger—hopefully fully vaccinated—social group sounds too much, try connecting with a friend you haven’t seen in a year with an hour-long picnic in the park. Once you feel comfortable with these smaller interactions, you can begin to safely expand your social network.

Another good rule of thumb is to know your boundaries and limits ahead of time as this will allow for some predictability and certainty. Ask yourself, what are you willing to tolerate? Is it the group size, rules around mask wearing, or the amount of time you are present? Acknowledging your boundaries and sticking to a plan can offer a good sense of confidence when you leave your home.

How can I tell if my anxiety about leaving the house is agoraphobia? What are the symptoms?

Agoraphobia is a clinical diagnosis under the umbrella of anxiety. This entails marked fear or anxiety across a number of situations whether that is going outside alone, using public transportation, standing in line, or being in large crowds or within closed spaces.

When there is fear of leaving the home, significant avoidance or behavioral modifications can develop. This can be turning down invitations, starting to self-medicate before leaving the home, or engaging in ‘safety behaviors’ such as only leaving the home with a trusted loved one.

How do I know if I should seek care for these feelings?

If current behaviors and emotions cause significant distress, impact daily functioning, or affect interpersonal relationships, it would be a good time to seek help from a trusted provider. Additionally, if self-medication—via drugs, alcohol, or even food—is necessary to white-knuckle your way through a task, seeking help would be important.

Telehealth services have expanded throughout the Mount Sinai Health System during the pandemic and this can be a wonderful way to begin psychotherapy for those with anxiety or agoraphobia. Working towards even just meeting in person with your provider is a great treatment goal at the start of these sessions.

Psychiatry Residents Win Multiple Awards

Psychiatry residents at the Icahn School of Medicine at Mount Sinai have been awarded several prestigious prizes and fellowships this year in recognition of their exceptional patient care, outstanding leadership, and remarkable research prowess.

Top row, left to right: Tim Becker, MD, PhD, (PGY-3); Sharely Fred-Torres, MD, (PGY-1); and Young Jung Kim, MD, PhD, (PGY-4). Bottom row, left to right: Isobel Rosenthal, MD, MBA, (PGY-2); Andrew Smith, MD, PhD, (PGY-3); Brian Sweis, MD, (PGY-1); and Genevieve Yang, MD, PhD (PGY-3).

Tim Becker, MD, PhD, (PGY-3) was selected as a 2021 American Psychiatric Association Foundation (APAF) Child and Adolescent Psychiatry Fellowship Program and won third place in a New York State Psychiatric Association Poster competition

Sharely Fred-Torres, MD, (PGY-1) was selected as a 2021-22 SAMHSA Minority Fellow through the APA Foundation.

Young Jung Kim, MD, PhD, (PGY-4) won second place in a New York State Psychiatric Association Poster competition.

Isobel Rosenthal, MD, MBA, (PGY-2) won an APA leadership award and a Group for Advancement of Psychiatry fellowship.

Andrew Smith, MD, PhD, (PGY-3) was admitted to the competitive Research Colloquium for Junior Psychiatrist Investigators through the APA.

Brian Sweis, MD, (PGY-1) won second place in the New York County Psychiatric Society Research Awards.

Genevieve Yang, MD, PhD (PGY-3) won an Outstanding Resident Program award from the NIMH and received a pilot grant from the ANRP at Mount Sinai.

Please join us in congratulating our exceptional residents!

 

 

Pregnancy and Antidepressants: Should You Avoid Taking Them?

Approximately half of women who use antidepressants before pregnancy decide to discontinue use either before or during pregnancy due to concerns about the negative consequences for their child.

Those who are pregnant or who may be thinking of getting pregnant may wonder if taking antidepressants could affect the heath of the child. New research from Mount Sinai offers some potentially important findings and shows that the underlying mental health of the parents is more of a concern than the medication itself.

The study shows that while there is a link between maternal antidepressant use during pregnancy and affective disorders in the child later in life, the link also exists between paternal antidepressant use during pregnancy and child mental health.

The data suggest the observed link is most likely due to the underlying mental illness of the parents rather than any “intrauterine effect,” which means any effect the medication could have on the fetus developing inside the uterus. These affective disorders include depression and anxiety.

“Our study does not provide evidence for a causal relationship between in-utero exposure to antidepressants and affective disorders in the child,” says Anna-Sophie Rommel, PhD, an instructor in the Department of Psychiatry at Icahn Mount Sinai and first author of the paper. “So, while other long-term effects of intrauterine exposure to antidepressants remain to be investigated, our work supports antidepressant continuation for women who would like to continue taking their medication, for example because of severe symptoms or a high risk of relapse. It is important to note that untreated psychiatric illness during pregnancy can also have negative consequences on the health and development of the child. Women and their health care providers should carefully weigh all of the treatment options and jointly decide on the best course of action.”

Anna-Sophie Rommel, PhD

Approximately half of women who use antidepressants before pregnancy decide to discontinue use either before or during pregnancy due to concerns about the negative consequences for their child, according to Dr. Rommel, who is also an expert in epidemiology and has been studying how the COVID-19 pandemic disproportionately affects pregnant women in underserved communities.

Major depressive disorder is highly prevalent, with one in five people experiencing an episode at some point in their life, and is almost twice as common in women than in men. Antidepressants are usually given as a first-line treatment, including during pregnancy, either to prevent the recurrence of depression, or as acute treatment in newly depressed patients. Antidepressant use during pregnancy is widespread and since antidepressants cross the placenta and the blood-brain barrier, concern exists about potential long-term effects of intrauterine antidepressant exposure in the unborn child.

Using the Danish National Registers to follow more than 42,000 babies born during 1998-2011 for up to 18 years, researchers at the Icahn School of Medicine at Mount Sinai investigated whether exposure to antidepressants in the womb would increase the risk of developing affective disorder like depression and anxiety in the child.

In a study published April 5 in Neuropsychopharmacology, the scientists found that children whose mothers continued antidepressants during pregnancy had a higher risk of affective disorders than children whose mothers stopped taking antidepressants before pregnancy.

However, to understand whether the underlying disorder for which the antidepressant was given or the medication itself was linked to the child’s risk of developing an affective disorder, they also studied the effect of paternal antidepressant use during pregnancy and similarly, found that children of fathers who took antidepressants throughout pregnancy had a higher risk for affective disorders. Thus, the research team speculates that rather than being an intrauterine effect, the observed link is most likely due to the parental mental illness underlying the antidepressant use.

A Vaccine Pod Dedicated to Mental Health Patients

From left: Raymond Rene, Office of Mental Health (OMH); Ruth Llanos, OMH Psychiatric Nurse; Paul Michael Avellaneda, OMH Psychiatric Nurse; Michelle Izmirly, DO; Gariy Livshits, OMH Treatment Team Leader

Earlier this year, the New York State Office of Mental Health (OMH) launched a program to bring vaccine doses to mental health patients, as many have trouble navigating the internet or don’t have smartphones and need help facilitating appointments. The OMH program was designed for patients to come to state psychiatric centers, but they were also eager to expand their reach and offered to set up vaccine pods at all OMH licensed clinics across the state. Michelle Izmirly, DO, Medical Director of Ambulatory Psychiatry at The Mount Sinai Hospital, reached out to OMH so that The Mount Sinai Hospital’s clinic could be included as a site.

“We see a very vulnerable patient population, and I knew a lot of our patients weren’t comfortable going to places like the Javits Center,” said Dr. Izmirly. “Some were even crying because they were so scared and so frustrated; often, they lacked internet access or cellular service to navigate the New York State vaccine eligibility website. We’re the ones they know. They know our setting and our staff, and they’re more comfortable getting the vaccine with us. They were so grateful that they had this option.”

It was a true team effort to pull it off. OMH scheduled a site visit to make sure the clinic had the appropriate setup: strong Wi-Fi, a comfortable area for injections, and supportive staff. Rajvee Vora, MD, Vice Chair of Clinical Affairs for the Department of Psychiatry, collaborated with Ania Wajnberg, MD, Medical Director of Ambulatory Care at The Mount Sinai Hospital and Site Lead for Vaccine Operations. They engaged the pharmacy and engineering departments to ensure the clinic had the appropriate equipment to safely store the vaccine.

Due to special efforts by Patricia Lamb, Chief of Ancillary and Support Services, Sue Mashni, PharmD, Chief Pharmacy Officer, and Michael Roche, PE, Senior Director of Engineering, the clinic space was converted to a safe and effective vaccine pod in one week. Eva Bayon, Administrative Manager, and Joan Bell, LCSW, Clinical Director of Ambulatory Psychiatry Services, handled the logistics of confirming and scheduling patients. Alicia Hurtado, MD, Associate Dean for Medical Student Wellness and Student Affairs, arranged for medical students to volunteer to monitor the patients for 15 minutes after they received the vaccination.

On April 8, the team vaccinated 72 patients—10 every 30 minutes starting at 9:30 am. And this might only be the beginning. The vaccine pod was such a success that OMH will return May 6 to reach the patients who were unable to attend their appointment that day. If OMH continues to provide the doses, the clinic could continue to offer it to their patients moving forward.

Cassidy Leverett, a care coordinator at the clinic, believes that the stability for these patients is key. “A lot of people find it really difficult to schedule the vaccine because it can be far from where they live or work, so it’s really great that people can go to a place they’re familiar with and see faces that they know. It’s been a very crazy time so it’s nice to have one stable place where you can go get your vaccine.”

Dr. Izmirly hopes this spreads beyond her clinic to other mental health clinics and practices. “You see so many news stories and research studies about people with mental illness contracting and dying from COVID-19 at higher rates than those who don’t suffer from mental illness,” she said. “We’ve even lost some of our own patients, which was completely devastating. This is an opportunity to help our own patients in our own settings, where we know they’ll feel comfortable.”

 

APA 2021: Presenters from Mount Sinai’s Department of Psychiatry

This year’s American Psychiatric Association conference takes place virtually May 1-3. The schedule of talks from Mount Sinai’s faculty is listed below.

 

Dr. Yehuda presenting at APA in 2019.

Sunday, May 2

Psychedelic-Assisted Psychotherapy for PTSD: Theory, Technique and Context

Presenter: Rachel Yehuda, PhD

Time: 4:00-5:30pm

 

Delivering HIV Prevention and Care to Transgender People: An Update

Presenters: Max Lichtenstein, MD, Kenneth Ashley, MD, and Carmen Cassanovas, MD

Time: 4:00-5:30pm

 

Monday, May 3

Friend, Frenemy, or Foe: The Role of Adolescent Social Media Use in Race Based Trauma

Presenter: Gabrielle Shapiro

Time: 11:30am-1:00pm

 

To Tweet or Not to Tweet: Social Media Use for Professional Development and for Mental Health Research
Presenter: Kara Bagot, MD

Time: 4:00-5:30pm

 

SOBP 2021: Presenters from Mount Sinai’s Department of Psychiatry

This year’s Society of Biological Psychiatry conference takes place virtually April 29-May 1. The schedule of talks from Mount Sinai’s faculty is listed below.

 

Thursday, April 29

Irritability Partly Accounts for the Association Between Pain and Depression: Findings From the EMBARC and STRIDE Studies and the VitalSign6 Project

Presenter: Manish Jha, MD

When: 5:15-5:30pm (Central Time)

 

Neurons from PTSD combat veterans (MAP2=magenta, GFAP=yellow, DNA=white). Image courtesy of Michael Breen, PhD.

Friday, April 30 

Inflammation and PTSD From the Macro to Microscale

Presenter: Michael Breen, PhD

When: 4:30-6:30pm (Central Time)

 

Advancing Treatment of Substance Use Disorders Through Computational Modeling

Presenter: Xiaosi Gu, PhD

When: 4:30-6:30pm (Central Time)

 

Irritability and Aggression in Psychiatric Illnesses: Translational Approaches in Identifying Novel Mechanisms and Treatment Targets

Chair: Manish Jha, MD

Presenter: Scott Russo, PhD

When: 4:30-6:30pm (Central Time)

 

Maternal Psychiatric Diagnosis and Comorbidities Around Pregnancy

Presenter: Vahe Khachadourian, MD, PhD

When: 5:45-6:00pm (Central Time)

 

An image from Dr. Frangou’s presentation.

Saturday, May 1

That’s a Wrap: Identifying Myelin as a Treatment Target in Psychosis Across Multiple Scales of Resolution

Presenter: Sophia Frangou, MD, PhD

When: 1:30-3:30pm (Central Time)

 

Bipolar Disorder: New Biological Insight and Potential Clinical Relevance From Large-Scale Genetic Studies

Presenter: Niamh Mullins, PhD

When: 1:30-3:30pm (Central Time)

 

Getting Motivated in Stressful Times

Presenter: Ming Hu Han, PhD

When: 5:00-7:00pm (Central Time)